ERBB2 and neoplasm: This tumor subset has been known for almost 20 years as “HER2 positive” breast cancers (3+ by immunohistochemistry (IHC), or 2+ by IHC and ErbB2 amplification by fluorescent in situ hybridization (FISH)).